Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: UGN-102 With or Without TURBT vs TURBT Alone in Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
2020-003541-11Phase 3Completed
- Sponsor
- UroGen Pharma
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zusduri in bladder cancer (3 arms), sponsored by UroGen Pharma. Primary endpoint: Disease-free survival. Started Dec 2020; status: completed.
02
Drugs
zusduri
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2020-003541-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003541-11.